Coherus Oncology Forecasts Q4 $13.12M Revenue and $0.31 EPS Loss
Coherus Oncology is expected to report a fourth-quarter loss of $0.31 per share on revenues of $13.12 million, representing a 75.8% year-over-year decline with consensus estimates unchanged over the past 30 days. It closed its public offering on February 17 and plans to present at investor conferences this month.
1. Q4 Earnings Expectations
Coherus Oncology is forecast to report a fourth-quarter loss of $0.31 per share on revenues of $13.12 million, marking a 75.8% decline compared to year-ago results. Consensus EPS and revenue estimates have remained stable over the past 30 days, reflecting investor skepticism around near-term performance.
2. Public Offering Activity
The company closed its public offering of common stock on February 17, issuing new shares to bolster its balance sheet. Details on the total proceeds raised were not disclosed, but the offering follows a pricing announcement made on February 12 that drove shares down 19.9% on February 13.
3. Upcoming Investor Engagements
Executives will present at several investor conferences later this month to discuss full-year outlook and strategic initiatives. These events may provide further details on clinical trial progress, cash runway projections, and potential partnerships to offset revenue headwinds.